Oct 31, 2023 by James Halley3 Green Flags and 1 Red Flag for Medical Properties TrustThe beleaguered healthcare REIT has made itself a less risky stock.
Oct 30, 2023 by James Halley5 Reasons Beam Therapeutics Remains a Risky StockShares of the gene-editing biotech might not have hit rock bottom yet.
Oct 28, 2023 by James HalleyRoche, Lilly or Pfizer: Who's the Winner in IBD Wars?The three companies are spending big on IBD therapies.
Oct 27, 2023 by James Halley2 Green Flags and 1 Red Flag for Novartis StockThe Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.
Oct 26, 2023 by James Halley3 Pharma Stocks That Are Screaming Buys in OctoberEach company delivers an above-average dividend and revenue growth.
Oct 25, 2023 by James Halley3 Dental Supply Stocks You Can Sink Your Teeth IntoLong-term trends and margin improvements are driving growth for dental supply companies.
Oct 23, 2023 by James Halley3 Stocks Cathie Wood Is Buying That Should Be on Your List TooThe three companies are positioned to benefit from red-hot trends.
Oct 21, 2023 by James HalleyWhich Is the Better Long-Term Hold for Investors: Pfizer or Roche?The venerable pharmaceutical companies' shares have slumped this year.
Oct 19, 2023 by James Halley3 Things About Bristol Myers Squibb That Smart Investors KnowThe stock is down this year, but will its struggles fade into the rearview mirror?
Oct 19, 2023 by James Halley4 Ways to Grow $100,000 Into $1 Million for RetirementInvesting for big-time growth doesn't have to be risky.
Oct 19, 2023 by James Halley3 Under-the-Radar Biotech Stocks to Buy in 2023These three lesser-known biotech companies are profitable and growing revenue.
Oct 19, 2023 by James HalleyWhich Is the Better Cannabis Growth Stock for You: Cresco Labs or TerrAscend?Cannabis stocks are back in style, but is either one of these multi-state operators a long-term buy?
Oct 14, 2023 by James Halley2 Robinhood Stocks With Market-Beating PotentialThese diamonds in the rough won't stay down.
Oct 13, 2023 by James HalleyWhy Shares of Revolution Medicines Were Popping on FridayThe company released positive phase 1/1b trial data on two cancer therapies.
Oct 13, 2023 by James HalleyWhy Shares of Harmony Bioscience Are Falling on FridayThe company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.
Oct 13, 2023 by James HalleyWhy Shares of T2 Biosystems Are Falling FridayA revenue drop and a reverse stock split worried investors.
Oct 12, 2023 by James HalleyWhy Shares of Insulet Dropped This WeekPositive news regarding diabetes therapy Ozempic worried investors.
Oct 12, 2023 by James HalleyWhy Akero Therapeutics Shares Are Slumping This WeekAkero's lead therapy fell short of its goals in a phase 2b trial to treat NASH.
Oct 12, 2023 by James HalleyWhy Shares of ProKidney Were Dropping ThursdayTwo factors led to the stock's slide on Thursday.
Oct 11, 2023 by James HalleyWhy Shares of Ardelyx Were Down WednesdayThe company's hopes for approval of a drug to treat chronic kidney disease took a hit.
